Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer

Barbara Bortot, 1 Maurizio Mongiat, 2 Erica Valencic, 3 Simeone Dal Monego, 4 Danilo Licastro, 4 Matteo Crosera, 5 Gianpiero Adami, 5 Enrico Rampazzo, 6 Giuseppe Ricci, 7, 8 Federico Romano, 7 Giovanni Maria Severini, 1 Stefania Biffi 7 1Department of Medical Genetics, Institute for Maternal and Ch...

Full description

Bibliographic Details
Main Authors: Bortot B, Mongiat M, Valencic E, Dal Monego S, Licastro D, Crosera M, Adami G, Rampazzo E, Ricci G, Romano F, Severini GM, Biffi S
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:International Journal of Nanomedicine
Subjects:
Online Access:https://www.dovepress.com/nanotechnology-based-cisplatin-intracellular-delivery-to-enhance-chemo-peer-reviewed-article-IJN
id doaj-7f0aedd8b96f4cc39cf6b7f98a62ffd6
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Bortot B
Mongiat M
Valencic E
Dal Monego S
Licastro D
Crosera M
Adami G
Rampazzo E
Ricci G
Romano F
Severini GM
Biffi S
spellingShingle Bortot B
Mongiat M
Valencic E
Dal Monego S
Licastro D
Crosera M
Adami G
Rampazzo E
Ricci G
Romano F
Severini GM
Biffi S
Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
International Journal of Nanomedicine
cisplatin resistance
ovarian cancer
skov3
nanoparticle
epithelial-mesenchymal transition
ca125
apoptosis
author_facet Bortot B
Mongiat M
Valencic E
Dal Monego S
Licastro D
Crosera M
Adami G
Rampazzo E
Ricci G
Romano F
Severini GM
Biffi S
author_sort Bortot B
title Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
title_short Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
title_full Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
title_fullStr Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
title_full_unstemmed Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
title_sort nanotechnology-based cisplatin intracellular delivery to enhance chemo-sensitivity of ovarian cancer
publisher Dove Medical Press
series International Journal of Nanomedicine
issn 1178-2013
publishDate 2020-07-01
description Barbara Bortot, 1 Maurizio Mongiat, 2 Erica Valencic, 3 Simeone Dal Monego, 4 Danilo Licastro, 4 Matteo Crosera, 5 Gianpiero Adami, 5 Enrico Rampazzo, 6 Giuseppe Ricci, 7, 8 Federico Romano, 7 Giovanni Maria Severini, 1 Stefania Biffi 7 1Department of Medical Genetics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 2Department of Research and Diagnosis, Division of Molecular Oncology, Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS, Aviano, Italy; 3Department of Pediatrics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 4ARGO Open Lab Platform for Genome Sequencing, AREA Science Park, Trieste, Italy; 5Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy; 6Department of Chemistry “G. Ciamician”, University of Bologna, Bologna, Italy; 7Department of Obstetrics and Gynecology, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 8Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, ItalyCorrespondence: Stefania Biffi Email stefania.biffi@burlo.trieste.itBackground: Platinum resistance is a major challenge in the management of ovarian cancer. Even low levels of acquired resistance at the cellular level lead to impaired response to cisplatin. In ovarian cancer intraperitoneal therapy, nanoparticle formulation can improve the cisplatin’s pharmacokinetics and safety profile.Purpose: This work aimed to investigate the chemo-sensitivity of ovarian cancer SKOV3 cells upon short-term (72h) single treatment of cisplatin and cisplatin-loaded biodegradable nanoparticles (Cis-NP). The aim was then to determine the therapeutic properties of Cis-NP in vivo using a SKOV3-luc cells’ xenograft model in mice.Methods: Cell cytotoxicity was assessed after the exposure of the cell culture to cisplatin or Cis-NP. The effect of treatments on EMT and CSC-like phenotype was studied by analyzing a panel of markers by flow cytometry. Intracellular platinum concentration was determined by inductively coupled plasma mass spectrometry (ICS-MS), and gene expression was evaluated by RNAseq analysis. The efficacy of intraperitoneal chemotherapy was evaluated in a SKOV3-luc cells’ xenograft model in mice, through a combination of bioluminescence imaging, histological, and immunohistochemical analyses.Results: We observed in vitro that short-term treatment of cisplatin has a critical role in determining the potential induction of chemoresistance, and a nanotechnology-based drug delivery system can modulate it. The RNAseq actg 3nalysis underlines a protective effect of nanoparticle system according to their ability to down-regulate several genes involved in chemoresistance, cell proliferation, and apoptosis. The highest intracellular platinum concentration obtained with Cis-NP treatment significantly improved the efficacy. Consistent with in vitro results, we found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug.Conclusion: Nanoparticle-mediated cisplatin delivery may serve as an intracellular depot impacting the cisplatin pharmacodynamic performance at cellular levels. These features may contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivo.Keywords: cisplatin resistance, ovarian cancer, SKOV3, nanoparticle, epithelial-mesenchymal transition, Ca125, apoptosis
topic cisplatin resistance
ovarian cancer
skov3
nanoparticle
epithelial-mesenchymal transition
ca125
apoptosis
url https://www.dovepress.com/nanotechnology-based-cisplatin-intracellular-delivery-to-enhance-chemo-peer-reviewed-article-IJN
work_keys_str_mv AT bortotb nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT mongiatm nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT valencice nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT dalmonegos nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT licastrod nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT croseram nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT adamig nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT rampazzoe nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT riccig nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT romanof nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT severinigm nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
AT biffis nanotechnologybasedcisplatinintracellulardeliverytoenhancechemosensitivityofovariancancer
_version_ 1724615990469197824
spelling doaj-7f0aedd8b96f4cc39cf6b7f98a62ffd62020-11-25T03:20:53ZengDove Medical PressInternational Journal of Nanomedicine1178-20132020-07-01Volume 154793481055123Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian CancerBortot BMongiat MValencic EDal Monego SLicastro DCrosera MAdami GRampazzo ERicci GRomano FSeverini GMBiffi SBarbara Bortot, 1 Maurizio Mongiat, 2 Erica Valencic, 3 Simeone Dal Monego, 4 Danilo Licastro, 4 Matteo Crosera, 5 Gianpiero Adami, 5 Enrico Rampazzo, 6 Giuseppe Ricci, 7, 8 Federico Romano, 7 Giovanni Maria Severini, 1 Stefania Biffi 7 1Department of Medical Genetics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 2Department of Research and Diagnosis, Division of Molecular Oncology, Centro Di Riferimento Oncologico Di Aviano (CRO) IRCCS, Aviano, Italy; 3Department of Pediatrics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 4ARGO Open Lab Platform for Genome Sequencing, AREA Science Park, Trieste, Italy; 5Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy; 6Department of Chemistry “G. Ciamician”, University of Bologna, Bologna, Italy; 7Department of Obstetrics and Gynecology, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; 8Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, ItalyCorrespondence: Stefania Biffi Email stefania.biffi@burlo.trieste.itBackground: Platinum resistance is a major challenge in the management of ovarian cancer. Even low levels of acquired resistance at the cellular level lead to impaired response to cisplatin. In ovarian cancer intraperitoneal therapy, nanoparticle formulation can improve the cisplatin’s pharmacokinetics and safety profile.Purpose: This work aimed to investigate the chemo-sensitivity of ovarian cancer SKOV3 cells upon short-term (72h) single treatment of cisplatin and cisplatin-loaded biodegradable nanoparticles (Cis-NP). The aim was then to determine the therapeutic properties of Cis-NP in vivo using a SKOV3-luc cells’ xenograft model in mice.Methods: Cell cytotoxicity was assessed after the exposure of the cell culture to cisplatin or Cis-NP. The effect of treatments on EMT and CSC-like phenotype was studied by analyzing a panel of markers by flow cytometry. Intracellular platinum concentration was determined by inductively coupled plasma mass spectrometry (ICS-MS), and gene expression was evaluated by RNAseq analysis. The efficacy of intraperitoneal chemotherapy was evaluated in a SKOV3-luc cells’ xenograft model in mice, through a combination of bioluminescence imaging, histological, and immunohistochemical analyses.Results: We observed in vitro that short-term treatment of cisplatin has a critical role in determining the potential induction of chemoresistance, and a nanotechnology-based drug delivery system can modulate it. The RNAseq actg 3nalysis underlines a protective effect of nanoparticle system according to their ability to down-regulate several genes involved in chemoresistance, cell proliferation, and apoptosis. The highest intracellular platinum concentration obtained with Cis-NP treatment significantly improved the efficacy. Consistent with in vitro results, we found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug.Conclusion: Nanoparticle-mediated cisplatin delivery may serve as an intracellular depot impacting the cisplatin pharmacodynamic performance at cellular levels. These features may contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivo.Keywords: cisplatin resistance, ovarian cancer, SKOV3, nanoparticle, epithelial-mesenchymal transition, Ca125, apoptosishttps://www.dovepress.com/nanotechnology-based-cisplatin-intracellular-delivery-to-enhance-chemo-peer-reviewed-article-IJNcisplatin resistanceovarian cancerskov3nanoparticleepithelial-mesenchymal transitionca125apoptosis